BioSpace News Archive

Harvard Chan School-Human Vaccines Project collaboration will use artificial intelligence and causal inference to accelerate drug and vaccine development

Post Acute Medical, which operates over 40 post-acute specialty hospitals across the country, has agreed to enable Cura Telehealth, a national telemedicine company, to use its properties to improve COVID-19 testing availability to the public during this time of high demand.

New Implantable Neurostimulator Decreases Recharge Interval to Only Once a Month

BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining certain features thought to expand the clinical applications of BriaCell’s genetically engineered whole-cell immunotherapies to those of infectious diseases including the SARS-CoV-2 virus that causes Coronavirus Disease 2019.

Given recently announced court closures and other restrictions due to the COVID-19 pandemic, the company would like to take this opportunity to provide an update on the ongoing litigation with Elysium Health.

MAESTRO Phase 3clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety and trial integrity during the COVID pandemic.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced a biopharma research partnership for AlloCell.

Sales of $20.7 billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated negative impact of the COVID-19 pandemic

Compugen Ltd. announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, for the treatment of advanced solid tumors in an oral presentation at the 2020 American Association for Cancer Research Virtual Annual Meeting I on April 27, 2020 at 11:45 AM EST.

MEI Pharma and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.; MEI to book U.S. sales on 50-50 profit and cost sharing